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End-stage renal disease (ESRD) is a serious illness with
significant health consequences and high-cost treatment
options. This study estimates direct and indirect cost
associated with ESRD from a societal perspective.
A prevalence-based approach was used to estimate direct
health-care costs and productivity losses from short- and
long-term disability. An incident-based human capital
approach was used to estimate mortality costs as the sum of
the discounted present value of current and future
productivity losses from premature deaths. Less than 0.1% of
Canadians have ESRD; however, the disease generated direct
health-care costs of $1.3 billion in the year 2000. The amount
of direct spending per person with ESRD is much more than
the average spending per person for all health-care
conditions. Adding indirect morbidity and mortality cost
brings the total burden associated with ESRD to $1.9 billion.
This economic impact is higher than that for skin or
infectious diseases, about the same as for genitourinary or
endocrine diseases, but lower than that for conditions such
as cancer or stroke. This economic weight is borne by a
relatively small number of individuals. With the rapid
increase in the incidence of ESRD, these findings may be
useful in setting priorities for research, prevention programs,
and in the planning of treatments. A better understanding of
the scope and magnitude of the total economic burden of
ESRD would help to inform those making policy decisions.
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About 10% of Canada’s gross domestic product is spent on
health services, but the economic burden of illness rises when
the effects of morbidity and premature mortality are taken
into account.1,2 This is particularly true for chronic diseases
where individuals live with the consequences of their disease
for years or decades.
End-stage renal disease (ESRD) exists when a person’s
original kidneys ‘are permanently impaired and can no
longer function normally to maintain life’, often defined as
functioning at less than 10% of their normal rate.3 Even with
treatment, it is a serious illness that often leads to poorer than
average health status and quality of life, significant financial
consequences, and high health-care costs.4–8 Previous re-
searchers have estimated total health-care costs for ESRD in a
few countries, but the additional impact of lost productivity
on the cost of illness has rarely been studied.9–14
Since the early 1980s, the number of Canadians with
ESRD has risen rapidly,3 leading to questions about the
current and future impact of the disease on public health,
quality of life, and health spending. This increase reflects
growth in both incidence (e.g. 181% more patients were
diagnosed with ESRD in 2000 than in 1985) and survival.15
This study measures the economic burden of ESRD in
Canada in 2000 in terms of direct spending on health care
(e.g. dialysis and hospital care), as well as indirect costs, such
as productivity losses due to premature death and short- and
long-term disability. The intent is to provide a broader
understanding of the effects of ESRD and how they compare
with other health conditions. The McMaster University
Research Ethics Board approved this study.
RESULTS
By the end of 2000, an estimated 24 921 Canadians were
living with ESRD.15 That year, renal centers cared for
approximately 4515 new ESRD cases and there were 2675
deaths.
The total economic burden of ESRD in Canada in 2000
was $1.9 billion (see Tables 1 and 2). Direct costs account for
most of the total (69%), reflecting the high health-care costs
for ESRD and the fact that many of those affected are past
their peak earning years. Indirect costs are also significant,
however, both for mortality (23%) and morbidity (8%).
Indirect costs are higher for patients on dialysis than for
those with transplants, reflecting the significant effect that
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being on dialysis often has on an individual’s ability to work,
as well as on life more generally.
Direct health-care costs
ESRD generated direct health-care expenditures of $1.3
billion in 2000. This includes $2 million for hospital costs,
physician surgery fees, and aftercare for living kidney donors;
$3 million for hospital and physician costs for cadaveric
kidney retrieval; $106 million for pretransplant care,
transplantation procedures, and ESRD care after transplanta-
tion in the year of transplant; $289 million for functioning
kidney transplant care in subsequent years; $646 million for
center hemodialysis and associated care; $80 million for self/
home hemodialysis and related services; and $147 million for
ESRD care for peritoneal dialysis patients. More than two-
thirds of direct health-care expenditures related to ESRD
(69%) were for persons on dialysis, although they accounted
for 58% of persons with ESRD. Consistent with previous
international research, center-based hemodialysis is more
expensive than other methods.16,17 In Canada, it accounts for
half of all ESRD care costs. Care for those on this type of
therapy costs more than twice that for someone with a
functioning transplant.
The amount spent on ESRD care represents about 1.3% of
Canada’s total health-care spending or just over 2% of what
provincial/territorial governments spent on health services in
2000.18 On a per capita basis, about $51 099 was spent on
ESRD care for each person with the disease (congruent with
methods used in similar studies,2 this total does not include
costs of care for unrelated conditions received by these
patients), significantly more than the average per person to
care for all conditions ($3183).
Indirect costs: lost productivity due to premature mortality
Over 2000 persons with ESRD died in 2000. The discounted
present value of future production lost due to their
premature deaths is estimated at $434 million. This is higher
than the totals Health Canada calculated for conditions such
as blood, musculoskeletal, and skin and related diseases
($19–126 million in 1998), but lower than those for major
causes of death such as cancer ($10 622 million) and
cardiovascular disease ($8250 million).2 As for many other
diseases, while most deaths occur in older age groups, deaths
among younger persons with ESRD contribute disproportio-
nately to the value of lost production due to premature
mortality. About 30% of those who died were under the age
of 65 but they accounted for 68% of mortality costs.
Additional analyses (see Table 3) show that ESRD
economic burden estimates are more sensitive to changes in
assumptions regarding discount rates than to those related to
labor productivity growth. For example, a 3–7% variation in
the discount rate leads to a $153 million difference in the
present value of lost production due to premature mortality.
However, neither set of assumptions had a substantial effect
on the total economic burden of illness.
Analyses were also conducted to test the sensitivity of
estimates of the economic burden of ESRD to the inclusion
of earnings from sources outside the labor market. Given that
sources of income such as the Canada/Quebec Pension Plans,
worker’s compensation, and unemployment insurance effec-
tively represent transfers, some argue that they should not be
included in estimates of the societal burden of illness since
they shift resources between individuals but do not change
society’s overall resources.19,20 Others contend that they
represent an approximation of the indirect cost of illness due
to disability.2,21 Removing them caused estimates of morta-
lity costs related to ESRD to fall only slightly. Simultaneously
dropping the value of unpaid labor had a more significant
effect, particularly for women and older persons. The total
mortality ‘cost’ based only on lost future paid labor market
earnings was $132 million, rather than $434 million.
Indirect costs: lost productivity due to morbidity
For the almost 25 000 Canadians who had ESRD in 2000,15
the disease had a significant impact on their lives. This
Table 1 | Direct health-care costs of end-stage renal disease in Canada in 2000
Category n
Inflation-adjusted
cost per capita in 2000 Baseline estimate
Direct health-care costs
Living kidney donorsa 389 $5890 $2 million
Cadaveric kidney retrieval (donors) 470 $5850 $3 million
Transplant care (year of transplant) 1105 $96 040 $106 million
Functioning transplant care (later years) 9249 $31 222 $289 million
Center hemodialysis 9752 $66 259 $646 million
Self/home hemodialysis 1568 $50 982 $80 million
Peritoneal dialysis 3247 $45 400 $147 million
Total direct costs $1273 million
aIncludes health-care costs for care of living donors only. Costs of transplantation and aftercare for recipients are included in the relevant entries.
Table 2 | Economic burden of end-stage renal disease in
Canada in 2000
Category Baseline estimate % of total
Direct costs $1273 million 69
Mortality costs $434 million 23
Morbidity costs $149 million 8
Total $1857 million 100
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translated into $149 million in estimated production losses
for paid and unpaid work. Notably, this figure is about the
same as Health Canada’s2 estimates for much more common
conditions, such as hip problems ($174 million in 1998) and
chronic obstructive pulmonary disease ($161 million),
reflecting the degree to which ESRD affects individuals’ lives.
The morbidity-related economic burden was much higher
for dialysis patients than for those with transplants. This is
because more people receive dialysis and they tend to
experience higher productivity losses. In 2000, an estimated
$113 million in productivity was lost due to morbidity for
patients on hemodialysis. A further $33 million was
attributed to peritoneal dialysis patients. The difference
between the two primarily reflects the number of patients
receiving each therapy. Both estimates are highly sensitive to
assumptions about productivity weights, but the impact on
the total economic burden of ESRD is modest (see Table 3).
Kidney transplant donors and recipients accrued a further
$3.3 million in short-term productivity losses in 2000. The
majority of these losses were attributed to transplant
recipients, mostly because of their larger numbers. For the
same reason, the sensitivity analyses that varied recovery time
for transplant patients had more effect than those that varied
the time that living donors spent off work. In both cases,
however, the changes had little impact on overall estimates of
the economic burden of ESRD.
DISCUSSION
Until relatively recently, communicable diseases, deaths in
childbirth, and trauma were leading causes of death, and
policies to improve health often focused on preventing the
spread of disease. Summary measures derived from vital
statistics, such as mortality rates and life expectancy, helped
to inform these decisions.22 As average life expectancy
lengthens, however, interest in promoting health throughout
the lifespan and in managing health-care costs has increased.
Estimates of the economic burden of illness attempt to
provide information needed to support this policy focus.
They explicitly combine both spending on health care and
productivity losses related to morbidity and premature
mortality. Results have been used for a variety of purposes,
including informing policy and research priorities and
decisions, estimating the relative societal impact of different
health conditions, and providing frameworks for program
evaluation.23
In the case of ESRD, the economic burden is substantial:
approximately $1.9 billion in Canada in 2000. While health
services account for most of these costs, ESRD-related
morbidity and premature mortality also impose a consider-
able burden on society. That said, without spending on ESRD
care, individuals with the disease would die, thereby
increasing premature mortality ‘costs’. This balance is
particularly evident for transplants. The surgery generates
relatively high short-term direct costs but tends to reduce
both health-care costs and indirect productivity losses in the
longer term.6
The magnitude of these trade-offs depends largely on the
method used to value productivity losses due to premature
mortality and morbidity. The human capital approach used
here is common in cost of illness studies, with results often
interpreted as conservative estimates of the total societal
welfare loss.2 Limitations of this method include the failure
to value intangibles (e.g. pain and suffering) except as they
lead to productivity losses, the difficulty of projecting
earnings potential over long periods, the inherent bias
toward diseases that tend to affect higher income earners,
concerns about whether lost actual and imputed earnings are
the best measure of production and/or welfare loss, and
questions about the extent to which absenteeism or death
reduces long-term economic production.23–26
A variety of alternatives have been proposed, each with
strengths and limitations. For example, the willingness to pay
method values human life based on how much people would
be willing to spend to reduce the probability of having the
consequences associated with a particular disease.27 This
approach tends to produce much larger estimates of indirect
cost, although estimates often differ depending on the group
consulted, over time, and by estimation method used.2 On
the other hand, the friction cost method tends to produce
much lower estimates of indirect costs. It assumes that
unemployed workers can be recruited to replace those who
are disabled or die.28 Productivity costs are therefore limited
to losses in output during a defined friction period while a
new worker is sought (e.g. 3 months), recruitment and
training costs, and any medium-term macroeconomic impact
resulting from labor market adjustments. Critics dispute the
assumptions on which this method is based and argue that it
does not consider full societal costs, depends heavily on the
economy’s unemployment level, and takes into account
Table 3 | Sensitivity of estimates of the economic burden of
ESRD in Canada in 2000 to changing assumptions ($ millions)
Variable
Change from baseline
assumptions
Resulting
estimate of the
economic
burden of ESRD
Baseline NA $1857
Discount rate applied
to the value of
future production
7–3% $1792–$1945
Labor productivity
growth
0.3 to 2.8% $1812–$1925
Lost productivity
related to
morbidity and
mortality
Include paid labor market
earnings only (e.g. exclude
value of unpaid work)
$1509
Disability weights
(extent of impact
of ESRD on
productivity)
Somewhat lower loss
(increase baseline weights
by 0.1) to somewhat higher
loss (decrease baseline
weights by 0.1)
$1820–$1895
Recovery time for
living organ donors
14–64 days off work $1856–$1857
Recovery time for
transplant recipients
3–10 weeks to resume
regular activities
$1856–$1858
ESRD, end-stage renal disease; NA, not applicable.
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neither the lost value of the recruited employee’s leisure time
nor intangibles (e.g. pain and suffering).29,30
While alternative valuation methods would change the
precise cost estimates, much of the value of cost of illness
studies is in assessing the relative burden of different health
conditions. As this study demonstrates, the total economic
burden of ESRD in Canada is higher than that for conditions
such as skin and infectious diseases, about the same as for
genitourinary and endocrine disease, and lower than for
diseases such as cancer and stroke.2 This weight is, however,
borne by a relatively small number of individuals. As a result,
the economic burden of ESRD is much higher per person
affected than for many other diseases. This is consistent with
the results of international research.9 In Canada, ESRD
treatment costs alone are estimated to be more than 16 times
what was spent on average per person to care for all health
conditions. Given the rapid rise in the number of persons
living with ESRD, this has important implications for
planning and policy design.
MATERIALS AND METHODS
This study measures the direct and indirect economic burden of
ESRD in Canada in 2000. The calculations take a societal
perspective, quantifying costs regardless of whether they fall on
individuals, employers, governments, or others. In order to facilitate
comparison with other diseases, the methods used parallel those
employed for a recent broad-based Canadian burden of illness
study,2 which in turn drew on protocols developed by a Task Force
of the US Public Health Service.31,32
A prevalence-based approach is used to estimate all direct health-
care costs and indirect morbidity costs related to ESRD. Thus totals
include costs incurred in 2000, regardless of the time of disease
onset. Mortality cost estimates are based on the discounted present
value of current and future production losses related to premature
deaths among those with ESRD in 2000, quantified using an
incidence-based human capital approach. This method sees
individuals as producing a stream of output over the years valued
at their earnings. Morbidity and mortality reduce or eliminate this
production.31,32
The direct and indirect cost calculations draw on many data
sources. The data cluster around the year 2000, the period for which
costs are calculated. Data from other years were adjusted to year
2000 dollars using a total health-care implicit price index18 for
health-care costs or the consumer price index.33
Direct health-care costs
Direct health-care costs represent the value of goods and services
used to prevent and/or treat illness that cannot, as a result, be put to
other uses. This study captures costs for organ retrieval, transplant
surgery and aftercare, and dialysis patients. Data on the number of
persons with ESRD by treatment modality in 2000 were obtained
from the Canadian Organ Replacement Register.
Total costs were calculated by multiplying the average cost per
procedure or course of treatment by the numbers who received each
type of care. Consistent with methods used in similar cost of illness
studies, to the extent possible, costs related to ESRD are isolated,
rather than including health care received by patients with ESRD for
unrelated health problems.2 This calculation sums the cost of
services related to ESRD, thereby excluding, for example, costs
related to a broken leg for an individual with a functioning
transplant. This approach avoids double counting (e.g. attributing
dialysis costs to both ESRD and hepatitis, which may be an
underlying risk factor), and hence facilitates cross-disease compar-
isons. Cost estimates were obtained from comprehensive national
sources or, when not possible, from individual provinces and/or
research studies (see Table 4). Using these types of data has the
advantage of leveraging broad-based representative cost estimates,
but less detail and flexibility is available than if purpose-specific
prospective costing data had been obtained (see Table 4 and
associated references for more details on included costs). Because of
changing practice patterns, cost data before the mid-1990s were
not used.
The result of these calculations is a somewhat conservative
estimate of health-care expenditures as the study primarily captures
costs borne by the health-care system. Patients or insurers may also
face other costs (e.g. for transportation to medical appointments or
renovations to accommodate home dialysis) that were not captured.
ESRD-related research costs also could not be disaggregated from
national sources. In addition, the significant costs associated with
running an organ donation and transplantation system (e.g. public
awareness campaigns) were not included because many are not
specific to kidney transplantation, because cost information was not
available, and for consistency with studies on the economic burden
of other illnesses.
Indirect costs: lost productivity due to premature mortality
In spite of many advances in treatment, persons with ESRD have a
shorter life expectancy than the population as a whole.34 Therefore,
in addition to direct health-care costs, this study estimates
premature mortality costs using an incidence-based human capital
approach. Thus, mortality costs are the sum of the present value of
lost production in the year of death and in subsequent years of
expected life for those with ESRD who died in 2000.
The Canadian Organ Replacement Register provided informa-
tion on the number of ESRD deaths in 2000 by sex for four age
groups (special tabulations). For estimation purposes, the average
age of ESRD patients in 2000 in each of the age groups was used to
combine death and productivity information. Life expectancy by age
and sex was derived based on recent data from Statistics Canada
using PMEDS-D (Version 2001.11.29). This software has been
described in detail elsewhere.35
Cost estimates include lost earnings from paid work, as well as
the imputed value of housekeeping and other untraded labor. They
draw on age- and sex-specific profiles of average earnings, workforce
participation, unpaid work, and life expectancy. To facilitate
comparisons with other health conditions, these profiles were based
on those assembled for the latest national study on the overall
economic burden of illness in Canada.2 This Health Canada study
used data on annual earnings for all years of expected life (based on
Statistics Canada’s Survey of Consumer Finances) and of the value of
unpaid work for 12 age groups by sex.
Baseline estimates assume that future labor productivity will
grow by 1.1% per year, a value chosen by Health Canada to reflect
Canadian historical rates over the preceding decade.2,36 A sensitivity
analysis was conducted with growth rates of 0.3 and 2.8%,
reflecting average annual labor productivity growth rates observed
in recent years.37,38
All scenarios assume that if those with ESRD had not had the
disease, they would have had the same potential average annual
economic output and the same labor force and housekeeping
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Table 4 | Sources of data on direct health-care costs
Type of cost Source Calculation method
Cost per person in year
2000 dollars
Fees paid to physicians in
private practice for a
nephrectomy and
subsequent outpatient
care for living donors
Research study56 Typical surgeon and anesthetist fees for a nephrectomy
using an open procedure were obtained from this recent
Ontario study, because these procedures were more
often used than laparoscopic procedures during the time
period for which the economic burden estimates were
calculated. In addition, less than $400 separated the
average physician fees for these two procedures in
2001,56 so changing this assumption would not have had
a material impact on overall estimates. This study was
also the source of outpatient costs for living donors for
the first 4 weeks after leaving hospital based on the
weighted average of cost estimates provided for patients
with and without pain at 4 weeks post-surgery. The
weights are based on the probability of pain for
donors who underwent open surgical procedures reported
in the study. Costs tracked in the study included physician
visit fees, clinic costs (visit costs and clinic space), and drug
and dispensing fee costs. Outpatient resource consumption
was gathered prospectively from the sample of patients
included in the study.
$907 ($786 for surgery fees
and $121 for aftercare)
Fees paid to physicians in
private practice for organ
retrieval from cadaveric
donors
Provincial fee-for-service
payment schedule59
Includes fees for nephrological management of donor
procurement, renal preservation for transplantation, and
removal of cadaveric kidneys based on the 1 September
2003 Ontario fee-for-service physician payment schedule.
(Ontario was selected for consistency with the source of
other physician cost estimates.) Under this schedule,
physicians can charge the provincial insurance plan for a
set of services related to ‘nephrological management of
donor procurement’, for renal preservation for
transplantation (assuming not performed by the
surgeon), and for removing cadaveric kidneys.
$867
Hospital costs for organ
retrieval
Canadian Institute for Health
Information60
Removal of a kidney from a living donor, regardless of the
surgical approach used, most often falls into Case Mix
Group 504 (Major Urinary Tract Procedures). The resource
intensity weight for this group and the mean cost per
weighted case were used to calculate the average cost of
a hospital stay. These weights are derived using costing
data primarily from hospitals in Ontario and Alberta,
combined with length of stay data from across the
country. They take into account hospitals’ fixed and
variable operating costs, such as wages and salaries;
laboratory, radiology, and other diagnostic tests; drugs
and medical supplies when provided in hospital;
accommodation and meals for patients; and the
operation and maintenance of hospitals’ acute care
facilities.60 Because the marginal cost of cadaveric kidney
donation was not available (multiple organs are often
harvested from a single donor), the same cost was used
for cadaveric donors.
$4983
Health-care costs for
transplant patients (those
who received surgery and
those with functioning
grafts)
Research study61 Study results used to estimate health-care costs related
to transplantation surgery (not including organ retrieval)
and aftercare. Costs were calculated by prospectively
recording resource use (based on data from patient
charts, provincial government billing systems, patient
interviews, and hospital cost data) for a sample of
patients who received transplants at three university
hospitals. Clinically stable patients who had been on a
waiting list for transplantation for at least 3 months were
eligible to be included in the study. Since transplants
occur throughout the year, direct health-care costs for
patients who received a transplant were assumed to be a
blended average of pre-transplant and post-transplant
maintenance costs, plus the costs of surgery. That is, on
average, transplants were assumed to have occurred
mid-way through the year.
$96 040 in the year of
transplant and $31 222 for
subsequent years with a
functioning transplant
Table 4 continued on following page.
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participation profiles as the population as a whole. Deaths were
assumed to occur, on average, at mid-year, with the value of
production in the year of death pro-rated accordingly. Future costs
were discounted because a dollar in the future is worth less than a
dollar today based on assumptions about time preference.39
Internationally, there has been considerable debate about the
appropriate discount rate to use.40–44 Baseline estimates in this
study use a discount rate of 5%, as recommended by the Canadian
Coordinating Office for Health Technology Assessment.45 To test the
sensitivity of results to this assumption, estimates were also
calculated for discount rates of 3 and 7%.
Indirect costs: lost productivity due to morbidity
In addition to having shorter than average life expectancy, persons
with ESRD are more likely to experience losses of short- or long-
term productivity.46,47 Using a human capital approach, indirect
costs were calculated for both organ donors and for individuals alive
with ESRD at the end of 2000 (based on their treatment status).
ESRD prevalence and treatment information by age group and sex
was obtained from the Canadian Organ Replacement Register. Since
the age distribution of Canadian living organ donors was not
available, the distribution reported by the United Network for
Organ Sharing in the United States for 2000 was applied to
Canadian totals.
To estimate the value of lost production, disability weights,
which reflect the extent of production lost, were multiplied by
average values of paid and unpaid work by age group and sex
(adjusted for labor force and housekeeping participation rates). This
approach assumes that if those with ESRD had not had the disease,
they would have produced the same average annual economic
output and had the same labor force and housekeeping participation
patterns as the overall population. Although many persons with
ESRD receive significant informal support from friends and family,
lost production for these individuals is not captured.7,48
As for the mortality cost calculations, labor force, income, and
unpaid work parameters from a study of the overall economic
burden of illness were used to facilitate comparability.2 Similar
disability weights were also used. This approach assigns weights
based on losses in autonomy using information derived from the
Quebec Health and Social Survey. These weights may overestimate
productivity losses for individuals who are able to adapt to their
condition and underestimate them for those who experience more
significant productivity effects (e.g. if the nature of their usual
activity is such that a schedule of center-based dialysis treatments
means that they cannot continue to participate in it).49
Since national data on disability levels for persons with ESRD
were not available, this analysis assigned disability weights and
imputed the average amount of time spent at given levels of
disability using findings from research studies. Sensitivity analyses
were conducted to test the effect of various assumptions on the
overall results. The studies used are as follows:
K Persons with functioning kidney transplants have a lower risk of
mortality and morbidity than those on dialysis.15,50–52 Several
studies have found that the quality of life of those with
functioning transplants is relatively comparable to the general
population.52–55 However, live donors and transplant recipients
experience short-term losses of productivity at the time of
surgery. Accordingly, live donors were assumed to be in hospital
and off work for the median periods (6 and 46 days respectively)
measured in a 2000 study of open nephrectomies in Toron-
to.56,57 A sensitivity analysis varied this assumption between the
minimum (14) and maximum (64) days observed in the study.
Consistent with methods used in studies of the overall economic
burden of illness,2 days in hospital were weighted at a
productivity level of 0.2 (i.e. individuals in hospital were
assumed to generate only 20% of their usual levels of paid and
unpaid production); other days off work were weighted at 0.5.
K Transplant recipients were assumed to be in hospital for 11 days,
the mean length of stay measured by the Canadian Institute for
Health Information’s Discharge Abstract Database in 2000/2001.
Recent studies on the average time to return to normal activities
for Canadian transplant recipients were not found. An estimate
of 6 weeks post-surgery (31 days post-discharge) was derived
from patient-information on the web sites of major interna-
tional transplant programs. The sensitivity analysis varied this
assumption from 3 to 10 weeks post-surgery. Productivity
weights of 0.5 were applied to this time.
K Patients on dialysis often experience sustained, long-term effects
on their ability to work or perform other activities. In the
absence of national data, results from an Alberta study were
used to assign disability weights for those on dialysis. This study
found that approximately 7% of hemodialysis patients and 5%
of peritoneal dialysis patients require 24-h/long-term care.58
These patients were assumed to have a ‘very severe’ disability
and assigned a productivity weight of 0.2. A further 31 and 35%,
respectively, required part-time home care. They were assumed
to have a ‘somewhat severe’ disability and assigned a
productivity weight of 0.5. Other dialysis patients were assigned
a weight of 0.7.
Table 4 | Continued
Type of cost Source Calculation method
Cost per person in year
2000 dollars
Costs of center-based
hemodialysis, limited care
and/or home
hemodialysis, and
peritoneal dialysis
Research studies16,62 Average costs for each type of dialysis were calculated
using the results of studies from British Columbia
(including dialysis treatment costs, plus additional costs
for laboratory, catheter, and other dialysis-related
services) and Toronto (including dialysis materials, clinical
and administrative staff related to dialysis care, overhead
and support, outpatient medications, hospital admission
and procedures, laboratory tests and medical imaging,
physician fees, and depreciation/capital costs). Other
studies were excluded from the calculation because of
the limited patient groups, costs, phases of treatment,
and/or time periods covered.
$66 259 for center-based
hemodialysis, $50 982 for
self/home hemodialysis, and
$45 400 for peritoneal
dialysis
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